Literature DB >> 11350482

Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count.

M K Jensen1, P de Nully Brown, B V Lund, O J Nielsen, H C Hasselbalch.   

Abstract

Platelet-leukocyte adhesion may occur as a consequence of platelet activation and possibly plays a key role in the deposition of activated platelets and fibrin in the thrombotic plug. The aim of the present study was to assess by whole blood flow cytometry the presence of circulating platelet-leukocyte aggregates (PLA) and the platelet-leukocyte response to platelet agonist stimulation (ADP and TRAP) in 50 patients with chronic myeloproliferative disorders (MPD) and 30 controls. PLA were identified as platelet-granulocyte/monocyte aggregates (PGMA), platelet-monocyte aggregates (PMA) and defined as the percentage of leukocytes coexpressing the platelet-specific marker glycoprotein Ib. Compared to controls the mean percentage of PGMA and PMA was increased in unstimulated whole blood from patients with MPD (7.98 vs. 1.76%; p<0.001 and 12.34 vs. 3.2%; p<0.001, respectively). The percentage of PGMA was correlated to the platelet count (r=0.46; p<0.001), percentage of P-selectin (r=0.69; p<0.001) and thrombospondin (r=0.58; p<0.001) positive platelets and platelet expression of GPIV (r=0.33; p=0.02). The mean percentage of PGMA and PMA was significantly increased in ADP-stimulated whole blood of patients (57.14 vs. 47.92%; p=0.009 and 54.91 vs. 45.89%; p<0.001, respectively). Compared to patients without a history of thrombosis, patients having experienced microvascular disturbances or a thrombotic event had a higher mean percentage of PGMA and PMA in non-stimulated whole blood (10.07 vs. 6.34%; p=0.025 and 14.81 vs. 10.48%; p=0.021, respectively) and a higher percentage of PGMA in ADP stimulated whole blood (64.32 vs. 51.50%; p<0.01). These data document an increased frequency of PLA in non-stimulated whole blood in MPD associated with a previous history of thrombosis or microvascular disturbances.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350482     DOI: 10.1034/j.1600-0609.2001.00359.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  25 in total

Review 1.  Blood cell activation in myeloproliferative neoplasms.

Authors:  Francisco Cervantes; Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 2.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

4.  Blood platelet and monocyte activations and relation to stages of liver cirrhosis.

Authors:  Anatol Panasiuk; Janusz Zak; Edwina Kasprzycka; Katarzyna Janicka; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

5.  Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood.

Authors:  Adam Z Blatt; Gurpanna Saggu; Koustubh V Kulkarni; Claudio Cortes; Joshua M Thurman; Daniel Ricklin; John D Lambris; Jesus G Valenzuela; Viviana P Ferreira
Journal:  J Immunol       Date:  2016-04-25       Impact factor: 5.422

6.  Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample.

Authors:  Aaron R Folsom; Nena Aleksic; Antonio Sanhueza; Eric Boerwinkle
Journal:  Atherosclerosis       Date:  2008-11-18       Impact factor: 5.162

7.  N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.

Authors:  Brianna M Craver; Gajalakshmi Ramanathan; Summer Hoang; Xinyue Chang; Laura F Mendez Luque; Stefan Brooks; Hew Yeng Lai; Angela G Fleischman
Journal:  Blood Adv       Date:  2020-01-28

8.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Authors:  Radhika Gangaraju; Jihyun Song; Soo Jin Kim; Tsewang Tashi; Brandi N Reeves; Krishna M Sundar; Perumal Thiagarajan; Josef T Prchal
Journal:  Blood Adv       Date:  2020-03-24

9.  Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation.

Authors:  Ioannis Kourtzelis; Klara Kotlabova; Jong-Hyung Lim; Ioannis Mitroulis; Anaisa Ferreira; Lan-Sun Chen; Bettina Gercken; Anja Steffen; Elisabeth Kemter; Anne Klotzsche-von Ameln; Claudia Waskow; Kavita Hosur; Antonios Chatzigeorgiou; Barbara Ludwig; Eckhard Wolf; George Hajishengallis; Triantafyllos Chavakis
Journal:  Thromb Haemost       Date:  2015-12-17       Impact factor: 5.249

10.  JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.

Authors:  Margarida Coucelo; Gonçalo Caetano; Teresa Sevivas; Susana Almeida Santos; Teresa Fidalgo; Celeste Bento; Manuela Fortuna; Marta Duarte; Cristina Menezes; M Letícia Ribeiro
Journal:  Int J Hematol       Date:  2013-11-26       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.